3The executive board has today discussed and approved the annual report of G2B BioSolutions ApS for the financial year 1 January - 31 December 2023.The annual report is prepared in accordance with the Danish Financial Statements Act.In my opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2023 and of the results of the company's operations for the financial year 1 January - 31 December 2023.In my opinion, management's review includes a fair review of the matters dealt with in the management's review.The financial statements have not been audited. Management considers the criteria for not auditing the financial statements to be met.Management recommends that the annual report should be approved by the company in general meeting.Dayanand Suryabhan JadhavDirectorTo the shareholder of G2B BioSolutions ApSWe have compiled the financial statements of G2B BioSolutions ApS for the financial year 1 January - 31 December 2023 based on the company's bookkeeping records and other information made available by enterprise. The financial statements comprises a summary of significant accounting policies, income statement, balance sheet, statement of changes in equity and notes. We performed the engagement in accordance with ISRS 4410, Compilation Engagements. We have applied our professional expertise to assist the enterprise in the preparation and presentation of the financial statements in accordance with the Danish Financial Statements Act. We complied with the relevant provisions of the Danish Act on Approved Auditors and with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), including principles relating to integrity, objectivity, professional competence and due care. The financial statements and the accuracy and completeness of the information used to compile the financial statements are the enterprise´s responsibility. As a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information provided by enterprise for our compilation of the financial statements. Accordingly, we do not express an audit or a review conclusion on whether the financial statements have been prepared in accordance with the Danish Financial Statements Act.Hellerup2024-04-04Søren JonassenState Authorized Public Accountantmne18488Business review The company's purpose is to conduct business with trade, service, production and thus, at the management's discretion, related business.Financial review The company's income statement for the year ended 31 December 2023 shows a loss of DKK 1.513.784, and the balance sheet at 31 December 2023 shows negative equity of DKK 1.720.976. The company has lost its share capital. A letter of support has been issued so that the company has ensured the financial preparedness to continue its operations until at least next balance date.Significant events occurring after the end of the financial year No events have occurred after the balance sheet date which could significantly affect the company's financial position.The annual report of G2B BioSolutions ApS for 2023 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B, as well as provisions applying to reporting class C entities. The accounting policies applied are consistent with those of last year.Income is recognised in the income statement as earned, including value adjustments of financial assets and liabilities. All expenses, including amortisation, depreciation and impairment losses, are also recognised in the income statement. Assets are recognised in the balance sheet when it is probable that future economic benefits will flow to the company and the value of the asset can be measured reliably. Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow from the company and the value of the liability can be measured reliably. On initial recognition, assets and liabilities are measured at cost. On subsequent recognition, assets and liabilities are measured as described below for each individual accounting item. Certain financial assets and liabilities are measured at amortised cost using the effective interest method. Amortised cost is calculated as the historic cost less any installments and plus/less the accumulated amortisation of the difference between the cost and the nominal amount. On recognition and measurement, allowance is made for predictable losses and risks which occur before the annual report is presented and which confirm or invalidate matters existing at the balance sheet date.In pursuance of section 32 of the Danish Financial Statements Act, the company does not disclose its revenue. Gross profit reflects an aggregation of revenue, and other operating income less cost of raw materials and consumables and other external expenses.Income from the sale of goods for resale and finished goods is recognised in the income statement, provided that the transfer of risk, usually on delivery to the buyer, has taken place and that the income can be measured reliably and is expected to be received. Revenue is measured at the fair value of the agreed consideration, excluding VAT and other indirect taxes. Revenue is net of all types of discounts granted.The item Other operating income includes items of a secondary nature relative to the company’s activities, including gains on the sale of intangible assets and items of property, plant and equipment, operating losses, indemnities relating to operating losses and conflicts as well as payroll refunds. Indemnities are recognised when it is more probable than not that the company is going to be indemnified.Other external expenses include expenses related to distribution, sale, advertising, administration, premises, bad debts etc.Staff costs include wages and salaries, including compensated absence and pensions, as well as other social security contributions, etc. made to the entity's employees.Financial income and expenses are recognised in the income statement at the amounts that relate to the financial year. Net financials include interest income and expenses, liabilities and foreign currency transactions, and surcharges and allowances under the Danish Tax Prepayment Scheme, etc.Tax for the year, which comprises the current tax charge for the year and changes in the deferred tax charge, is recognised in the income statement as regards the portion that relates to the profit/loss for the year and directly in equity as regards the portion that relates to entries directly in equity.Investment in subsidiaries are measured at cost. If cost exceeds the recoverable amount, a write-down is made to this lower value.Receivables are measured at amortised cost. An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable is impaired, an impairment loss for that individual asset is recognised.Prepayments recognised under 'Current assets' comprises expenses incurred concerning subsequent financial years.Cash and cash equivalents comprise deposits at banks.Dividends Proposed dividends are disclosed as a separate item under equity. Dividends are recognised as a liability when declared by the annual general meeting of shareholders.Current tax liabilities and current tax receivables are recognised in the balance sheet as the estimated tax on the taxable income for the year, adjusted for tax on the taxable income for previous years and tax paid on account. The company and all its Danish group entities are taxed on a joint basis. The current income tax charge is allocated between the jointly taxed entities relative to their taxable income. Tax losses are allocated based on the full absorption method. The jointly taxed entities are eligible for the Danish Tax Prepayment Scheme. Deferred tax is measured according to the liability method in respect of temporary differences between the carrying amount of assets and liabilities and their tax base, calculated on the basis of the planned use of the asset and settlement of the liability, respectively. Deferred tax is measured at net realisable value. Deferred tax assets, including the tax base of tax losses allowed for carry forward, are measured at the value to which the asset is expected to be realised, either as a set-off against tax on future income or as a set-off against deferred tax liabilities within the same legal tax entity. Any deferred net tax assets are measured at net realisable value.Liabilities, which include trade payables and other payables, are measured at amortised cost, which is usually equivalent to nominal value.On initial recognition, foreign currency transactions are translated applying the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and at the date of payment are recognised in the income statement as financial income or financial expenses. If foreign currency instruments are considered cash flow hedges, any unrealised value adjustments are taken directly to a fair value reserve under ‘Equity’.-739652-17118476175841374-1501410-212558123744794-1513784-21735201200-1513784-218552-1513784-2185524000004000004000004706629953125460005019148995018509501916750490191675044000040000-1760976-247191-1720976-2071915000000500000018551106883315000105682325969513111672746951811167274695901916750440000-247192-151378440000-1760976747766403111287856811144957617584137421012004000004000000000400000Name Registered office Share capital Ownership interest Equity Profit/loss for the year G2b biosolutions denmark aps Hellerup 40000 100 29.902 -10.098G2b biosolutions denmark apsHellerup10029902-10098050000000The company has lost its share capital. A letter of support has been issued so that the company has ensured the financial preparedness to continue its operations until at least next balance date.The company is jointly taxed with its parent company, Dayanad Jadhav Holding ApS (management company), and jointly and severally liable with other jointly taxed entities for payment of income taxes as well as for payment of withholding taxes on dividends which fall due for payment on. The company has no contingent liabilities.None.Årsrapport33256876CroweRygårds Allé 1042900 Hellerup2023-01-012023-12-312022-01-012022-12-3142437069G2B BioSolutions ApSHagens Alle72900HellerupDKDanmark2021-06-03GentofteCrowe33256876Søren JonassenState Authorized Public AccountantRygårds Allé1042900HellerupDKDanmark39292500info@crowe.dk2024-04-10Dayanand Suryabhan JadhavRegnskabsklasse BtrueAndre erklæringer uden sikkerhedCaseWare-FSR424370692023-01-012023-12-31424370692023-01-012023-12-311424370692022-01-012022-12-31424370692022-12-31424370692023-12-31424370692023-01-01h:InvestmentsInGroupEnterprisesMember424370692022-01-01h:InvestmentsInGroupEnterprisesMember424370692023-12-31h:InvestmentsInGroupEnterprisesMember424370692022-12-31h:InvestmentsInGroupEnterprisesMember424370692023-01-012023-12-311424370692023-01-01h:ContributedCapitalMember424370692023-12-31h:ContributedCapitalMember424370692023-01-01h:RetainedEarningsMember424370692023-01-012023-12-31h:RetainedEarningsMember424370692023-12-31h:RetainedEarningsMember424370692023-12-31h:ConvertibleProfitYieldingOrDividendYieldingLongtermDebtInstrumentsMember424370692023-01-01h:ConvertibleProfitYieldingOrDividendYieldingLongtermDebtInstrumentsMember424370692023-01-012023-12-31h:SubsidiaryMember1424370692023-12-31h:SubsidiaryMember1iso4217:DKKxbrli:pure